InChI key
JWBOIMRXGHLCPP-UHFFFAOYSA-N
InChI
1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H
SMILES string
ClC(Cl)C(c1ccc(Cl)cc1)c2ccccc2Cl
grade
analytical standard
packaging
ampule of 250 mg
manufacturer/tradename
Chem Service, Inc. PS-694
Gene Information
rat ... Ar(24208)
Looking for similar products? Visit Product Comparison Guide
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
F Menaa et al.
Current medicinal chemistry, 19(34), 5854-5862 (2012-09-01)
Adrenocortical carcinoma (ACC) is a rare but aggressive malignancy with a poor prognosis. Treatment options for advanced ACC are limited. Indeed, radical tumor resection can lead to local or metastatic recurrence, and mitotane (Lysodren(®)), the only recognized adrenolytic drug, offers
A fly in the ointment: reassessing mitotane's role in the treatment of adrenocortical carcinoma.
Aditi A Bapat et al.
Pharmacogenomics, 13(11), 1207-1209 (2012-08-28)
Vasileios Chortis et al.
The Journal of clinical endocrinology and metabolism, 98(1), 161-171 (2012-11-20)
Mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane] is the first-line treatment for metastatic adrenocortical carcinoma (ACC) and is also regularly used in the adjuvant setting after presumed complete removal of the primary tumor. Mitotane is considered an adrenolytic substance, but there is limited information on
Matthias Kroiss et al.
The Journal of clinical endocrinology and metabolism, 97(10), 3495-3503 (2012-07-28)
Treatment of refractory adrenocortical carcinoma (ACC) is not established. Animal experiments pointed toward adrenal toxicity of sunitinib. The objective of the study was to determine the antitumor effects of sunitinib in refractory ACC. This was a phase II, open-label trial
David E Schteingart et al.
Anticancer research, 32(7), 2711-2720 (2012-07-04)
Mitotane is used in adrenal cancer as adjuvant therapy, monotherapy or combined with other cytotoxic agents in advanced disease, but only 30% of patients respond. The aim of this study was to define the structural requirements for drug activity and
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service